FDA NEWS

Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent - MSN MoneyCentral
- FIRAZYR peak annual global sales expected to be around $350-400 million, based on current expectation of the competitive environment Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that Maia
Source: news.moneycentral.msn.com

Fighting Tooth and Nail - Baltimore Sun
I t's a relatively small change - a rewritten page buried deep in the Food and Drug Administration Web site that will list possible health hazards from the use of mercury in dental fillings. But for a small, vocal group of advocates, it's the
Source: www.baltimoresun.com

FDA Approves Abbott's Xience V Drug Eluting Stent - Phramalive.com
XIENCE V, Only Drug Eluting Stent to Demonstrate Superiority Over Market-Leading Stent in Clinical Trials, Now Available in United States for Treatment of Coronary Artery Disease ABBOTT PARK, Ill., July 02, 2008 /PRNewswire-FirstCall/ -- Abbott today
Source: www.pharmalive.com

Adolor Provides Update on Entereg(R) (alvimopan) OBD Program - MSN MoneyCentral
The U. S. Food and Drug Administration (FDA) has concluded that clinical investigations relating to alvimopan in OBD may now proceed, and has therefore lifted the clinical hold on the OBD Investigational New Drug Application. “ After a productive
Source: news.moneycentral.msn.com

2nd UPDATE: Skyepharma Up On Third Positive Flutiform Study - CNN Money
LONDON -(Dow Jones)- Shares in U.K. pharmaceuticals company Skyepharma PLC ( SKP.LN) rose more than 10% Thursday after it successfully completed its third phase III study of asthma drug, Flutiform. Just one trial now remains before the company can
Source: money.cnn.com

FDA warns farms on antibiotic use - Newsday
Inspectors found a common antibiotic has been misused in animals through practices such as injections into chicken eggs and ordered farmers to stop the unapproved treatments because of the risk to humans. The drugs, called cephalosporins, were given
Source: www.newsday.com

FDA backs Abbott stent - Chicago Tribune
While U.S. approval of Abbott Laboratories ' drug-coated heart stent is a boost to the North Chicago medical giant, the product enters a market that is shrinking as doctors rethink the role of artery-clearing devices in the prevention of heart
Source: www.chicagotribune.com

Phytopharm sees FDA submission for weight product Hoodia in late 2009 - CNBC
LONDON (Thomson Financial) - Phytopharm Plc. said it expects Hoodia extract, its weight management product partnered with Anglo-Dutch giant Unilever, to progress towards submission to the U.S. Food and Drug Administration by late in 2009. In an
Source: www.cnbc.com